Mesoblast Limited vs First Trust Cloud Computing ETF — how do they compare? Mesoblast Limited trades at $16.79 (market cap $2.21B), while First Trust Cloud Computing ETF trades at $162.04. The key difference: First Trust Cloud Computing ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | SKYY | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | — |
52-Week High | $20.96 | $161.09 |
52-Week Low | $12.88 | $104.16 |
Enterprise Value | $2.21B | — |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
SKYY trades at $161.62, up 0.52% today, with a bullish technical signal from moving averages but overbought RSI levels. The ETF provides diversified exposure to cloud computing, benefiting from AI adoption and cloud migration trends. Recent news highlights strong inflows into technology ETFs and AI-driven growth in cloud infrastructure.
The outlook for SKYY remains positive due to secular tech trends, though overbought conditions and competition from European tech sovereignty initiatives pose risks. Analyst sentiment is generally favorable, focusing on long-term growth in cloud and AI sectors.
Trailing returns across standard periods
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →